摘要
目的探讨不同疗程CIK治疗肿瘤患者CIK细胞体外抗肿瘤作用的差异.方法分离多疗程和单疗程CIK治疗肿瘤患者的外周血单个核细胞(PBMC),加入细胞因子诱导CIK细胞,用MTT法检测其对不同肿瘤细胞株的杀伤活性,用流式细胞仪检测其免疫表型.结果不同疗程患者的CIK细胞对肿瘤细胞都有一定细胞毒活性,当患者行多疗程治疗时,效靶比在4:1、8:1和16:1时,对BGC-823和SPC-A-1的细胞毒性较单疗程强,但以SPC-A-1低效靶比4:1时差异更为明显.另外,多疗程组的CD3+CD56+细胞含量显著高于单疗程组(P<0.05).结论多疗程CIK治疗患者的CIK细胞对肿瘤细胞的杀伤效果强于单疗程CIK治疗患者,多次CIK治疗延长肿瘤患者生存期,提高生活质量,对肿瘤复发有较好的作用.
Objective To investigate the differences in anti-tumor effect of CIK cells in vitro among cancer patients with different course of CIK treatments.Methods Peripheral blood mononuclear cells（PBMC）were separated from cancer patients with multi-course and single-course CIK treatments,and then were induced by cytokines.Tumor cell killing activity was detected by MTT assay.Surface antigens expression was detected by flow cytometry.Results CIK in patients with different course of CIK treatment had cytotoxic activity on tumor cells to a certain extent.When effector target ratio was 4：1,8：1 and 16：1,the cytotoxicity to BGC-823 and SPC-A-1 of CIK cells from patients with multiple courses treatment was stronger than single course treatment.When effector target ratio was 4：1,the difference in the cytotoxicity to SPC-A-1 of CIK cells was more obvious.In addition,CD3＋CD56＋ cells of patients with multiple treatment group were significantly higher than patients with the single treatment（P0.05）.Conclusion The cytotoxic activities to tumor cells of CIK cells from multiple treatment patients were higher than those of single treatment patients.This indicats that repeated treatment can prolong survival of tumor patients,which can improve the quality of life and has a good effect in prevention of tumor recurrence.
出处
《昆明医学院学报》
2010年第12期37-40,共4页
Journal of Kunming Medical College
基金
昆明市科技局重点项目(08S090203)
